Package Leaflet: Information for the Patient
Amversio 1 g Oral Powder
anhydrous betaine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
Amversio contains anhydrous betaine, which is indicated as a supplement in the treatment of homocystinuria, a hereditary (genetic) disease in which the body is unable to break down the amino acid methionine completely.
Methionine is present in the proteins of normal foods (such as meat, fish, milk, cheese, eggs). It is converted into homocysteine, which is then usually converted into cysteine during digestion. Homocystinuria is a disease caused by the accumulation of homocysteine that is not converted into cysteine, and is characterized by the formation of blood clots in the veins, bone weakness, and skeletal and lens anomalies. The use of Amversio, along with other treatments such as vitamin B6, vitamin B12, folate, and a specific diet, aims to reduce high levels of homocysteine in your body.
Do not take Amversio
if you are allergic to anhydrous betaine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Amversio.
Other medicines and Amversio
Tell your doctor if you are taking, have recently taken, or might take any other medicines.
If you are using an amino acid mixture or medicines such as vigabatrin or GABA analogs (medicines used to treat epilepsy), inform your doctor, as they may interact with your Amversio treatment.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. Your doctor will decide whether you can use the medicine during pregnancy and breastfeeding.
Driving and using machines
Amversio has no or negligible influence on the ability to drive and use machines.
The use of this medicine will be supervised by a doctor with experience in the treatment of patients with homocystinuria.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
The recommended dose in children and adults is 100 mg/kg/day in two doses per day. In some patients, doses higher than 200 mg/kg/day may be necessary to achieve therapeutic goals. Your doctor may adjust the dose based on laboratory values.
Therefore, you will need to have blood tests periodically to determine the correct daily dose.
Instructions for use
You must take Amversio orally (by mouth).
To measure the dose:
Mix the measured dose of powder with water, juice, milk, infant formula, or food until it is completely dissolved, and take it immediately after mixing.
If you take more Amversio than you should
If you accidentally take too much Amversio, inform your doctor or pharmacist immediately.
If you forget to take Amversio
Do not take a double dose to make up for forgotten doses. If you forget to take a dose, take it as soon as you remember, and continue with the next dose as scheduled.
If you stop taking Amversio
Do not stop treatment without consulting your doctor. Consult your doctor or pharmacist before stopping treatment.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The level of methionine may be related to brain inflammation (cerebral edema), which can affect up to 1 in 100 people (uncommon). If you experience morning headaches with vomiting and/or visual disturbances, consult your doctor immediately (they may be signs of cerebral inflammation).
Other side effects include:
Very common: may affect more than 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label of the bottle and carton after EXP. The expiry date is the last day of the month stated.
Store in the original package.
Keep the bottle tightly closed to protect it from moisture.
This medicine does not require any special storage temperature.
Once the bottle is opened, the medicine should be used within 3 months.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Amversio
Appearance and pack contents
Amversio is a white crystalline powder that flows freely. It is presented in a child-resistant closure bottle. Each bottle contains 180 g of powder. Each carton contains one bottle and three measuring spoons.
The green measuring spoon dispenses 100 mg.
The blue measuring spoon dispenses 150 mg.
The purple measuring spoon dispenses 1 g
Marketing authorisation holder and manufacturer
Marketing authorisation holder
SERB S.A.
Avenue Louise 480
1050 Brussels
Belgium
Manufacturer
MoNo Chem-Pharm Produkte GmbH,
Leystraße 129,
1200 Vienna
Austria
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website http://www.emea.europa.eu. There are also links to other websites on rare diseases and orphan medicines.